Overall rank by patents
#9,431
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Aligos Therapeutics, Inc.
USPTO PatentsView assignee record - 33 granted patents across 9 technology areas, active 2021–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
33
Total patents granted
9
CPC technology areas
23.2
Avg claims per patent
-
5-year filing velocity
The verdict
Aligos holds 33 US patents across 9 technology areas, rank #9,431 of 50,000 tracked assignees.
- #9,431
- of 50,000 US assignees by volume
- Top 6%
- by Innovation Score (56.7/100)
- 23.2
- avg claims per patent
Portfolio overview
Aligos Therapeutics, Inc. has been granted 33 US utility patents between 2021 and 2025, placing Aligos Therapeutics, Inc. at rank #9,431 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Aligos Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 56.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2025, with 33 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Aligos Therapeutics, Inc.'s 23.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Aligos Therapeutics, Inc. against peers pursuing similar technology classes.
How does Aligos compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Aligos Therapeuti… ◀ 33
Aligos Therapeutics, Inc.
33 patents
What this shows Aligos holds 33 patents, placing it at rank #9,431 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Aligos's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
57 Top 6% higher than 94% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2021–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 6 | 18.2% |
| 2022 | 2 | 6.1% |
| 2023 | 13 | 39.4% |
| 2024 | 9 | 27.3% |
| 2025 | 3 | 9.1% |
Which technologies does Aligos Therapeutics, Inc. patent most?
Top 9 of 9 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Frequently Asked Questions
How many patents does Aligos Therapeutics, Inc. hold?
Aligos Therapeutics, Inc. holds 33 US granted patents filed between 2021 and 2025, spanning 9 technology areas.
What is Aligos Therapeutics, Inc.'s Innovation Score?
Aligos Therapeutics, Inc. has an Innovation Score of 56.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Aligos Therapeutics, Inc. focus on?
Aligos Therapeutics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 29 patents. The company has filed patents in 9 CPC subclasses total.
Is Aligos Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Aligos Therapeutics, Inc..
What does claim depth mean for Aligos Therapeutics, Inc.'s patents?
Aligos Therapeutics, Inc.'s patents average 23.2 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Aligos Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
How to use this portfolio
Aligos's 33 grants land it in the top 6% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Aligos ranks #9,431 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61P technology
Aligos Therapeutics, Inc.'s primary CPC class, all holders and yearly trends
Top 50 patent holders
See where Aligos Therapeutics, Inc. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
